ArticleNPJ precision oncology2021

A phase I/II study of rovalpituzumab tesirine in delta-like 3-expressing advanced solid tumors.

Aaron S Mansfield et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.